Maharashtra continues to be the worst-affected state.

Maharashtra tops the tally with 232 fatalities, followed by Gujarat at 77, Madhya Pradesh at 76, Delhi at 47, Rajasthan at 25, Telangana at 23 and Andhra Pradesh at 22.

The number of active COVID-19 cases stood at 15,859. While 3,959 people have been cured and discharged, and one patient has migrated, the ministry said.

The number of active COVID-19 cases stood at 20,177 while 5,913 people (21.96 percent) were cured and discharged, and one patient has migrated, the ministry said.The total number of cases include 111 foreign nationals.Of the 47 deaths reported since Saturday evening, 22 are from Maharashtra, eight in Rajasthan, seven from Madhya Pradesh, six Gujarat and one each from Delhi, Uttar Pradesh, Jammu and Kashmir and Tamil Nadu.

During the daily media briefing, Lav Agarwal, Joint Secretary, Union Health and Family Welfare Ministry, said that 16 districts in the country, which earlier had cases, have not reported any fresh cases for the last 28 days.

Of the 937 deaths, Maharashtra tops the tally with 369 fatalities, followed by Gujarat at 162, Madhya Pradesh at 113, Delhi at 54, Rajasthan at 46 and Andhra Pradesh and Uttar Pradesh at 31 each.

There has been a spike of 1,813 cases since Tuesday evening.The number of active COVID-19 cases stand at 22,982, while 7,796 people have recovered, and one patient has migrated, the health ministry said.

Of the 1,075 deaths, Maharashtra tops the tally with 432 fatalities, followed by Gujarat at 197, Madhya Pradesh at 130, Delhi at 56, Rajasthan at 51, Uttar Pradesh at 39 and Andhra Pradesh at 31.

Phase 1 will include a considerable easing of measures that will allow people to move around their province as well as attend concerts and go to the theatre. Gatherings of up to 10 people will be allowed

Collector directs the PSUs to hold mock drill on disaster preparedness within a week

State registers 48 deaths, the highest in a day

Coronavirus in Tamil Nadu: Death toll rises to 44, state reports 526 more positive cases

Covid-19 toll not being under-reported, says AAP government

‘They can operate with 33% workforce in red zones, including GHMC area’

Globally, as of 9 May 2020, there have been 3,862,676 confirmed cases, including 265,961 deaths, reported to WHO.

Autor:
Erschienen
BSB-Signatur Clm 18565

URN: urn:nbn:de:bvb:12-bsb00131315-7
URL: http://daten.digitale-sammlungen.de/~db/0013/bsb00131315/images/

Maharashtra tops the tally with 779 deaths

The incident took place back in 2014 during India's test match against New Zealand.

Maharashtra has the highest number of cases with around 20,228 positive cases of infection and 779 deaths.

Of the 2,109 fatalities, Maharashtra tops the tally with 779 deaths. Gujarat comes second with 472 deaths, followed by Madhya Pradesh at 215, West Bengal at 171, Rajasthan at 106, Uttar Pradesh at 74, Delhi at 73, and Andhra Pradesh and Tamil Nadu at 44.

Five days after nearly 5,500 cases of liquor seized by police went missing in Sonipat, Haryana Police on Saturday raided the Chandigarh hideout of the godown owner's husband and seized Rs 97 lakh, a Range Rover car, two pistols and a three mobile phones.

The solvated centrosymmmtric title compound, [Li2(C24H34O4P)2(C10H8N2)2]·2C7H8, was formed in the reaction between {Li[(2,6-iPr2C6H3-O)2POO](MeOH)3}(MeOH) and 2,2'-bi­pyridine (bipy) in toluene. The structure has monoclinic (P21/n) symmetry at 120 K and the asymmetric unit consists of half a complex mol­ecule and one mol­ecule of toluene solvent. The diaryl phosphate ligand demonstrates a μ-κO:κO'-bridging coordination mode and the 2,2'-bi­pyridine ligand is chelating to the Li+ cation, generating a distorted tetra­hedral LiN2O2 coordination polyhedron. The complex exhibits a unique dimeric Li2O4P2 core. One isopropyl group is disordered over two orientations in a 0.621 (4):0.379 (4) ratio. In the crystal, weak C—H⋯O and C—H⋯π inter­actions help to consolidate the packing. Catalytic systems based on the title complex and on the closely related complex {Li[(2,6-iPr2C6H3-O)2POO](MeOH)3}(MeOH) display activity in the ring-opening polymerization of ∊-caprolactone and l-dilactide.

The new title one-dimensional CdII coordination polymer, [Cd(C10H10N2)2(μ1,3-N3)2]n, has been synthesized and structurally characterized by single-crystal X-ray diffraction. The asymmetric unit consists of a CdII ion, one azide and one 1-benzyl­imidazole (bzi) ligand. The CdII ion is located on an inversion centre and is surrounded in a distorted octa­hedral coordination sphere by six N atoms from four symmetry-related azide ligands and two symmetry-related bzi ligands. The CdII ions are linked by double azide bridging ligands within a μ1,3-N3 end-to-end (EE) coordination mode, leading to a one-dimensional linear structure extending parallel to [100]. The supra­molecular framework is stabilized by the presence of weak C—H⋯N inter­actions, π–π stacking [centroid-to-centroid distance of 3.832 (2) Å] and C—H⋯π inter­actions between neighbouring chains.

In the title hydrated complex, [Co(C15H10ClN3)2]Cl2·4H2O, the complete dication is generated by overline{4} symmetry. The CoN6 moiety shows distortion from regular octa­hedral geometry with the trans bond angles of two N—Co—N units being 160.62 (9)°. In the crystal, O—H⋯Cl and C—H⋯O inter­actions link the components into (001) sheets. The title compound exhibits blue-light emission, as indicated by photoluminescence data, and a HOMO–LUMO energy separation of 2.23 eV was obtained from its diffuse reflectance spectrum.

The redetermined structure [for the previous study, see: Godfrey & Waters (1975). Cryst. Struct. Commun. 4, 5–8] of ammonium μ-oxido-μ-[1,5,6-tri­hydroxy­hexane-2,3,4-tris­(olato)]bis­[dioxidomolybdenum(V)] monohydrate, NH4[Mo2(C6H11O6)O5]·H2O, was obtained from an attempt to prepare a glutamic acid complex from the [Co2Mo10H4O38]6− anion. Subsequent study indicated the complex arose from a substantial impurity of mannitol in the glutamic acid sample used. All hydrogen atoms have been located in the present study and the packing displays N—H⋯O, O—H⋯O and C—H⋯O hydrogen bonds. A Hirshfeld surface analysis was also performed.

The non-steroidal anti-inflammatory drugs mefenamic acid (MFA) and tolfenamic acid (TFA) have a close resemblance in their molecular scaffold, whereby a methyl group in MFA is substituted by a chloro group in TFA. The present study demonstrates the isomorphous nature of these compounds in a series of their multicomponent solids. Furthermore, the unique nature of MFA and TFA has been demonstrated while excavating their alternate solid forms in that, by varying the drug (MFA or TFA) to coformer [4-di­methyl­amino­pyridine (DMAP)] stoichiometric ratio, both drugs have produced three different types of multicomponent crystals, viz. salt (1:1; API to coformer ratio), salt hydrate (1:1:1) and cocrystal salt (2:1). Interestingly, as anticipated from the close similarity of TFA and MFA structures, these multicomponent solids have shown an isomorphous relation. A thorough characterization and structural investigation of the new multicomponent forms of MFA and TFA revealed their similarity in terms of space group and structural packing with isomorphic nature among the pairs. Herein, the experimental results are generalized in a broader perspective for predictably identifying any possible new forms of comparable compounds by mapping their crystal structure landscapes. The utility of such an approach is evident from the identification of polymorph VI of TFA from hetero-seeding with isomorphous MFA form I from acetone–methanol (1:1) solution. That aside, a pseudopolymorph of TFA with di­methyl­formamide (DMF) was obtained, which also has some structural similarity to that of the solvate MFA:DMF. These new isostructural pairs are discussed in the context of solid form screening using structural landscape similarity.

As researchers investigate the impact of the Burmese python in the Everglades, scientists from the Smithsonian Institution, South Florida Natural Resources Center and the University of Florida examined the snake’s predation of the area’s birds. They found that birds, including endangered species, accounted for 25 percent of the python’s diet in the Everglades.

The post Invasive Burmese pythons are taking a toll on Florida’s native birds appeared first on Smithsonian Insider.

A new study of microorganisms living on the skin and in the intestines of North America vultures (black and turkey vultures) has turned up a […]

The post Vultures remarkably tolerant to deadly bacteria, study reveals appeared first on Smithsonian Insider.

The post How do paleontologists identify dinosaur teeth? Smithsonian Curator Matthew Carrano identifies Cretaceous dinosaur teeth from the Washington D.C. area. appeared first on Smithsonian Insider.

The post Conrad Labandiera, Smithsonian palentologist, studies fossils to learn how insects got along before flowering plants arrived appeared first on Smithsonian Insider.

The post How do paleontologists reconstruct environments from the ancient past? appeared first on Smithsonian Insider.

Meet Nick Pyenson, one of our paleontologists at the National Museum of Natural History. His job as a time traveler is to make discoveries about […]

The post Time Travel With Smithsonian Paleontologist: Nick Pyenson appeared first on Smithsonian Insider.

An error in an equation in the paper by Song et al. [Acta Cryst. (2019), C75, 1353–1358] is corrected.

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.